



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 47/14 // (A61K 47/14, 47:14)	A1	(11) International Publication Number: WO 99/32153 (43) International Publication Date: 1 July 1999 (01.07.99)
(21) International Application Number: PCT/US98/27052 (22) International Filing Date: 17 December 1998 (17.12.98) (30) Priority Data: 60/068,411 22 December 1997 (22.12.97) US (71) Applicant: ALZA CORPORATION [US/US]; 950 Page Mill Road, P.O. Box 10950, Palo Alto, CA 94303-080 (US). (72) Inventors: BESTE, Russell; 381 Farley Street, Mountain View, CA 94043 (US). HAMLIN, Richard; 7471 Braidburn Avenue, Newark, CA 94560 (US). (74) Agents: RAFA, Michael, J. et al.; Alza Corporation, 950 Page Mill Road, P.O. Box 10950, Palo Alto, CA 94303-0802 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: MONOGLYCERIDE AND ETHYL PALMITATE PERMEATION ENHANCER COMPOSITIONS		
(57) Abstract Compositions, devices, and methods for transdermal administration of a drug are disclosed using a novel permeation enhancer mixture comprising a monoglyceride and ethyl palmitate. The monoglyceride/ethyl palmitate permeation enhancer is a potent permeation enhancer and provides stable systems which are more readily characterized. Additionally, ethyl palmitate cosolvent systems are more readily processed at manufacturing conditions thus providing further advantages over other cosolvents.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

1
2
3
4
5
6
7
8
9
10
11

MONOGLYCERIDE AND ETHYL PALMITATE
PERMEATION ENHANCER COMPOSITIONS

TECHNICAL FIELD

12
13
14
15
16
17
18
19

This invention relates to the transdermal delivery of drugs and more particularly to methods and compositions for enhancing the percutaneous absorption of drugs when incorporated in transdermal drug delivery systems or devices. More particularly and without limitation, this invention relates to the transdermal delivery of drugs utilizing a novel permeation enhancer comprising a monoglyceride, preferably glycerol monolaurate, and ethyl palmitate as a cosolvent.

20
21

BACKGROUND ART

22
23
24
25
26
27
28
29
30

The transdermal route of parenteral delivery of drugs provides many advantages, and transdermal systems for delivering a wide variety of drugs are described in U.S. Pat. Nos. 3,598,122; 3,598,123; 3,731,683; 3,797,494; 4,286,592; 4,314,557; 4,379,454; 4,435,180; 4,559,222; 4,568,343; 4,573,999; 4,588,580; 4,645,502; 4,704,282; 4,816,258; 4,849,226; 4,908,027; 4,943,435; 5,004,610; 5,006,342; 5,314,694; 5,411,740; 5,629,019; 5,641,504; 5,686,097 for example, all of which are incorporated herein by reference. In many cases, drugs which would appear to be ideal candidates for transdermal delivery are

1 found to have such low permeability through intact skin that they cannot be
2 delivered in therapeutically effective amounts from reasonably sized devices.

3 In an effort to increase skin permeability so that drugs can be delivered in
4 therapeutically effective amounts, it has been proposed to pretreat the skin with
5 various chemicals or to concurrently deliver the drug in the presence of a
6 permeation enhancer. Various materials have been suggested for this, as
7 described in U.S. Patent Nos. 3,472,931; 3,527,864; 3,896,238; 3,903,256;
8 3,952,099; 4,046,886; 4,130,643; 4,130,667; 4,299,826; 4,335,115; 4,343,798;
9 4,379,454; 4,405,616; 4,568,343; 4,746,515; 4,764,379; 4,788,062; 4,820,720;
10 4,863,738; 4,863,970; 4,865,848; 4,900,555; 4,940,586; 4,973,468; 5,053,227;
11 5,059,426; 5,378,730; and WO 95/01167, all of which are hereby incorporated in
12 their entirety by reference. Williams et al. "Skin Absorption Enhancers" Critical
13 Review in Therapeutic Drug Carrier Systems, pp. 305-353 (1992) and Santus et
14 al. "Transdermal Enhancer Patent Literature", Journal of Controlled Release, pp.
15 1-20 (1993) also provide a recent review of transdermal permeation enhancers.

16 To be considered useful, a permeation enhancer should have the ability to
17 enhance the permeability of the skin for at least one and preferably a significant
18 number of drugs. More importantly, it should be able to enhance the skin
19 permeability such that the drug delivery rate from a reasonably sized system
20 (preferably 5 - 60 cm²) is at therapeutically effective levels. Additionally, the
21 permeation enhancer when applied to the skin surface, should be non-toxic, non-
22 irritating on prolonged exposure and under occlusion, and non-sensitizing on
23 repeated exposure. Preferably, it should be odorless, physiologically inactive,
24 and capable of delivering drugs without producing burning or tingling sensations.

25 In addition to these permeation enhancer-skin interaction considerations,
26 a permeation enhancer must also be evaluated with respect to possible
27 interactions within the transdermal system itself. For example, the permeation
28 enhancer must be compatible with the drug to be delivered, the adhesive, and
29 the polymer matrix in which the drug is dispersed. The permeation enhancer

1 should also be selected so as to ensure a suitable balance among tack,
2 adhesion, and cohesive strength of the adhesive.

3 The use of a cosolvent in combination with a permeation enhancer has
4 also been disclosed in the prior art. Such cosolvents may not appreciably
5 increase transdermal flux by themselves, but act synergistically to increase the
6 transdermal flux of a drug when used in combination with other permeation
7 enhancers such as monoglycerides. One theory is that these cosolvents act to
8 increase the availability of the permeation enhancer at the skin surface, thus
9 providing increased flux of drug.

10 For example, US,WO 95/09006 discloses the use of various lactic acid
11 ester cosolvents such as lauryl lactate, ethyl lactate, cetyl lactate, and myristyl
12 lactate in combination with a monoglyceride. However, these lactic acid esters
13 may be irritating to the skin. Further, these lactate esters are not commercially
14 available at a high degree of purity, thus causing regulatory concerns as they are
15 not readily characterized.

16 WO 96/40259 discloses the use of lauryl acetate as a cosolvent for
17 monoglyceride permeation enhancers such as GML. This combination provides
18 enhanced flux when compared to other monoglyceride / cosolvent combinations
19 and is available at a high degree of purity.

20 However, lauryl acetate has been found to be an undesirable cosolvent
21 from a manufacturing standpoint. For example, it has been found that an
22 undesirable amount of lauryl acetate evaporates during manufacturing of
23 transdermal systems due to its high vapor pressure, leaving insufficient amounts
24 of lauryl acetate in the system.

25 Therefore, in spite of these advances, problems associated with skin
26 irritation and more recently discovered problems associated with processing and
27 manufacturing of films comprising various cosolvents for monoglycerides have
28 left a need for improved monoglyceride / cosolvent combinations.

29 Additionally, US Patent No. 5,312,122 discloses the use of
30 monoglycerides and fatty acid esters, alone or in combination, as a permeation

1 enhancer mixture for ST 1435, a synthetic progestogen. Specific fatty acid
2 esters or desirable properties are not disclosed.

3 U.S. Patent No. 5,026,556 discloses a composition for the transdermal
4 delivery of buprenorphine comprising an amount of buprenorphine in a carrier
5 comprising a polar solvent material selected from the group consisting of C₃-C₄
6 diols, C₃-C₆ triols, and mixtures thereof; and a polar lipid material selected from
7 the group consisting of fatty alcohol esters, fatty acid esters, and mixtures
8 thereof. Ethyl palmitate is disclosed as a suitable polar lipid material.

9 U.S. Patent No. 5,352,456 discloses a transdermal device which provides
10 an initial pulse of drug followed by a substantially lower continuous rate. The
11 device comprises a drug reservoir comprising the drug dissolved in a carrier and
12 a volatile permeation enhancer. The volatile permeation enhancer is depleted
13 from the reservoir by evaporation through the backing layer causing the decrease
14 in drug delivery rate. The volatile permeation enhancers are described as
15 comprising a vapor pressure of greater than about 10 mm Hg at 25° C.

16 U.S. Patent No. 5,149,538 discloses the transdermal delivery of an
17 opioid. Preferred permeation enhancers are saturated and unsaturated fatty
18 alcohols, fatty alcohol esters, or fatty acids having 8-18 carbon atoms.

19 U.S. Patent No. 5,650,165 discloses percutaneous absorption
20 preparations comprising an acrylic copolymer, a fatty acid ester comprising a
21 higher fatty acid having 12 - 16 carbon atoms and a lower monohydric alcohol
22 having 1 - 4 carbon atoms, and a monoglyceride comprising a higher fatty acid
23 having 8 - 10 carbon atoms.

24 U.S. Patent No. 5,747,069 discloses a percutaneous absorbable
25 preparation containing a drug and an absorption accelerator comprising a
26 monoglyceride and a fatty acid. All of the aforementioned patents are
27 incorporated herein in their entirety by reference.

1

2

DESCRIPTION OF TERMS

3

4 As used herein, the term "drug" is to be construed in its broadest sense to
5 mean any material which is intended to produce some biological, beneficial,
6 therapeutic, or other intended effect, such as permeation enhancement, for
7 example, on the organism to which it is applied.

8 As used herein, the term "individual" intends a living mammal and
9 includes, without limitation, humans and other primates, livestock and sports
10 animals such as cattle, pigs and horses, and pets such as cats and dogs.

11 As used herein, the term "monoglyceride" refers to a monoglyceride or
12 mixture of monoglycerides of C₁₂ - C₂₀ fatty acids and includes, without limitation,
13 glycerol monolaurate (GML), glycerol monooleate (GMO), and glycerol
14 monolinoleate (GMLO).

15 As used herein, the term "permeation enhancement" intends an increase
16 in the permeability of skin to a drug in the presence of a permeation enhancer as
17 compared to permeability of skin to the drug in the absence of a permeation
18 enhancer.

19 As used herein, the term "permeation enhancer" intends an agent or a
20 mixture of agents which, alone or in combination, acts to increase the
21 permeability of the skin to a drug.

22 As used herein, the term "permeation-enhancing" intends an amount or
23 rate of a permeation enhancer which provides permeation enhancement
24 throughout a substantial portion of the administration period.

25 As used herein, the phrase "predetermined area of skin" intends a defined
26 area of intact unbroken skin or mucosal tissue. That area will usually be in the
27 range of about 5 cm² to about 100 cm².

28 As used herein, the phrase "sustained time period" intends at least about
29 12 hours and will typically intend a period in the range of about one to about
30 seven days.

1 As used herein, the term "therapeutically effective" amount or rate refers
2 to the amount or rate of drug needed to effect the desired therapeutic result.

3 As used herein, the term "transdermal" refers to the use of skin, mucosa,
4 and/or other body surfaces as a portal for the administration of drugs by topical
5 application of the drug thereto.

6

7

SUMMARY OF THE INVENTION

8

9 According to the present invention, it has been discovered that the
10 combination of a monoglyceride permeation enhancer and ethyl palmitate as a
11 cosolvent results in a permeation enhancer which provides enhanced
12 transdermal flux for a variety of drugs. The use of ethyl palmitate as a cosolvent
13 for monoglyceride permeation enhancers has been found to unexpectedly result
14 in superior transdermal flux compared to other monoglyceride / cosolvent
15 mixtures such as GML and lauryl acetate. Additionally, ethyl palmitate does not
16 vaporize during process manufacture to the same extent as other cosolvents
17 such as dodecyl acetate, thus is preferred from a manufacturing standpoint.

18 The invention provides novel compositions for use with transdermal drug
19 delivery devices and methods for effectively administering drugs and greatly
20 increasing the drug permeability through the skin while reducing the lag time
21 between application of the drug to the skin and attainment of the desired
22 therapeutic effect.

23 Accordingly, the present invention provides compositions and devices for
24 transdermal administration of at least one drug to the systemic circulation of a
25 patient, at a therapeutically effective rate, by permeation through a body surface
26 or membrane, comprising at least one drug and a permeation-enhancing amount
27 of a permeation enhancer comprising a monoglyceride in combination with ethyl
28 palmitate as a cosolvent. The invention further provides a method for the
29 transdermal coadministration of a drug at a therapeutically effective rate together

1 with a skin permeation-enhancing amount of the monoglyceride/ethyl palmitate
2 permeation enhancer.

3 While it is known in the art to combine permeation enhancers, this
4 invention utilizes a novel combination of a monoglyceride and ethyl palmitate.
5 Preferred monoglycerides include glycerol monolaurate (GML), glycerol
6 monooleate (GMO), and glycerol monolinoleate (GMLO). Glycerol monolaurate is
7 a particularly preferred monoglyceride.

8 Therefore, it is an aspect of the present invention is to provide improved
9 drug delivery by means of transdermal systems and compositions.

10 It is accordingly an aspect of this invention to provide a permeation
11 enhancer composition for use in transdermal compositions, methods, and
12 devices which provides for the transdermal coadministration of a drug at a
13 therapeutically effective rate with improved in vivo efficacy.

14 It is another aspect of this invention to provide a permeation enhancer
15 composition for use in transdermal compositions, methods, and devices
16 comprising a monoglyceride and a cosolvent wherein the cosolvent is stable and
17 obtainable at a high degree of purity, thus resulting in systems which are more
18 readily characterized.

19 A further aspect is to increase the transport of drugs across the skin
20 following application of a transdermal therapeutic system.

21 Another aspect is to eliminate the lag time between the application of a
22 transdermal therapeutic system and attainment of the desired therapeutic flux
23 level.

24 Another aspect is to improve ease of manufacture of transdermal systems
25 and compositions comprising permeation enhancers.

26 It is yet another aspect of this invention to provide a permeation enhancer
27 composition for use in transdermal compositions, methods, and devices which
28 provides consistent results from one lot of formulations to another.

29 Therefore, the invention comprises the following aspects, either alone or in
30 combination:

1 A composition of matter for transdermally delivering at least one drug at a
2 therapeutically effective rate by permeation through a body surface or membrane
3 comprising, in combination:

4 (a) at least one drug; and

5 (b) a permeation-enhancing amount of a permeation enhancer comprising
6 a monoglyceride and ethyl palmitate, wherein the drug and permeation enhancer
7 are dispersed within a carrier.

8 A device for the transdermal administration of at least one drug at a
9 therapeutically effective rate by permeation through a body surface or
10 membrane, comprising:

11 a) a drug reservoir comprising at least one drug and a permeation-
12 enhancing amount of a permeation enhancer comprising a monoglyceride and
13 ethyl palmitate;

14 b) a backing on or adjacent the skin distal surface of the drug reservoir;

15 c) means for maintaining the reservoir in drug- and permeation enhancer -
16 transmitting relation with the body surface or membrane.

17 The compositions and devices according to this invention preferably
18 comprise a drug selected from the group consisting of anxiolytics,
19 anticholinergics, analgesics, and anti-spasmodics such as testosterone,
20 estradiol, progesterone, fentanyl, oxybutynin, and buspirone; a monoglyceride
21 selected from the group consisting of glycerol monooleate, glycerol
22 monolinoleate, and glycerol monolaurate. Additionally, the means for
23 maintaining the reservoir in drug- and permeation enhancer -transmitting relation
24 with the body surface or membrane comprises an in-line adhesive or the drug
25 reservoir comprises a pressure sensitive adhesive which also provides said
26 means for maintaining the reservoir in drug- and permeation enhancer -
27 transmitting relation with the body surface or membrane. The devices and
28 compositions may also comprise about 1-15% by weight of a water absorbing
29 polymer such as polyvinyl pyrrolidone and polyvinyl alcohol. Other suitable water
30 soluble and water absorbing polymers are known in the art, such as those

1 disclosed in U.S. Patent No. 5,176,916, hereby incorporated in its entirety by
2 reference.

3 Additionally, the invention is directed to a method for the transdermal
4 administration of at least one drug at a therapeutically effective rate comprising
5 simultaneously coadministering to a body surface or membrane a drug and a
6 permeation enhancing amount of a permeation enhancer comprising a
7 monoglyceride and ethyl palmitate.

8 These and other aspects and advantages of this invention will be readily
9 apparent from the following description with reference to the accompanying
10 figures.

11

12

BRIEF DESCRIPTION OF THE DRAWINGS

13

14 FIG. 1 is a cross-sectional view of one embodiment of a transdermal
15 therapeutic drug delivery device which may be used in accordance with the
16 present invention.

17

18 FIG. 2 is a cross-sectional view of another embodiment of a transdermal
19 therapeutic drug delivery device which may be used in accordance with the
20 present invention.

21

22 FIG. 3 is a cross-sectional view of yet another embodiment of a
23 transdermal therapeutic drug delivery device which may be used in accordance
24 with this invention.

25

26

27

28

MODES FOR CARRYING OUT THE INVENTION

29

30 According to the invention, it has been found that a combination of a
monoglyceride and ethyl palmitate can be used to effectively enhance the
permeability of drugs through body surfaces and particularly through the skin.

1 Specifically, it has been found that monoglycerides and ethyl palmitate enhance
2 the permeability of the skin such that therapeutically effective amounts of a drug
3 can be delivered from reasonably sized devices at therapeutically effective rates.
4 Additionally, ethyl palmitate has a higher molecular weight and lower vapor
5 pressure than prior art monoglyceride cosolvents such as lauryl acetate, thus
6 being superior from a manufacturing standpoint.

7 The system of the invention is preferably a transdermal drug delivery
8 device comprising a matrix adapted to be placed in drug- and permeation
9 enhancer-transmitting relation with a body surface or membrane such as the skin
10 or mucosa. The system must be of a size useful for the application of the drug
11 and the enhancer to a human body.

12 The utility of a monoglyceride / ethyl palmitate permeation enhancer has
13 been demonstrated for a variety of different drugs as seen in the Examples that
14 follow. It is believed that this invention has utility in connection with the delivery
15 of drugs within the broad class normally delivered through body surfaces and
16 membranes, including skin. In general, this includes therapeutic agents in all of
17 the major areas, including, but not limited to, ACE inhibitors, adenohipophoseal
18 hormones, adrenergic neuron blocking agents, adrenocortical steroids, inhibitors
19 of the biosynthesis of adrenocortical steroids, alpha-adrenergic agonists, alpha-
20 adrenergic antagonists, selective alpha-two-adrenergic agonists, analgesics,
21 antipyretics and anti-inflammatory agents, androgens, local and general
22 anesthetics, antiaddictive agents, antiandrogens, antiarrhythmic agents,
23 antiasthmatic agents, anticholinergic agents, anticholinesterase agents,
24 anticoagulants, antidiabetic agents, antidiarrheal agents, antidiuretic, antiemetic
25 and prokinetic agents, antiepileptic agents, antiestrogens, antifungal agents,
26 antihypertensive agents, antimicrobial agents, antimigraine agents,
27 antimuscarinic agents, antineoplastic agents, antiparasitic agents,
28 antiparkinson's agents, antiplatelet agents, antiprogestins, antithyroid agents,
29 antitussives, antiviral agents, atypical antidepressants, azaspirodecanediones,
30 barbituates, benzodiazepines, benzothiadiazides, beta-adrenergic agonists, beta-

1 adrenergic antagonists, selective beta-one-adrenergic antagonists, selective
2 beta-two-adrenergic agonists, bile salts, agents affecting volume and
3 composition of body fluids, butyrophenones, agents affecting calcification,
4 calcium channel blockers, cardiovascular drugs, catecholamines and
5 sympathomimetic drugs, cholinergic agonists, cholinesterase reactivators,
6 dermatological agents, diphenylbutylpiperidines, diuretics, ergot alkaloids,
7 estrogens, ganglionic blocking agents, ganglionic stimulating agents, hydantoins,
8 agents for control of gastric acidity and treatment of peptic ulcers, hematopoietic
9 agents, histamines, histamine antagonists, 5-hydroxytryptamine antagonists,
10 drugs for the treatment of hyperlipoproteinemia, hypnotics and sedatives,
11 immunosuppressive agents, laxatives, methylxanthines, monoamine oxidase
12 inhibitors, neuromuscular blocking agents, organic nitrates, opioid analgesics and
13 antagonists, pancreatic enzymes, phenothiazines, progestins, prostaglandins,
14 agents for the treatment of psychiatric disorders, retinoids, sodium channel
15 blockers, agents for spasticity and acute muscle spasms, succinimides,
16 thioxanthines, thrombolytic agents, thyroid agents, tricyclic antidepressants,
17 inhibitors of tubular transport of organic compounds, drugs affecting uterine
18 motility, vasodilators, vitamins and the like.

19 Representative drugs include, by way of example and not for purposes of
20 limitation, bepridil, diltiazem, felodipine, isradipine, nicardipine, nifedipine,
21 nimodipine, nitredipine, verapamil, dobutamine, isoproterenol, carterolol,
22 labetalol, levobunolol, nadolol, penbutolol, pindolol, propranolol, sotalol, timolol,
23 acebutolol, atenolol, betaxolol, esmolol, metoprolol, albuterol, bitolterol,
24 isoetharine, metaproterenol, pirbuterol, ritodrine, terbutaline, alclometasone,
25 aldosterone, amcinonide, beclomethasone dipropionate, betamethasone,
26 clobetasol, clocortolone, cortisol, cortisone, corticosterone, desonide,
27 desoximetasone, 11-desoxycorticosterone, 11-desoxycortisol, dexamethasone,
28 diflorasone, fludrocortisone, flunisolide, fluocinolone, fluocinonide,
29 fluorometholone, flurandrenolide, halcinonide, hydrocortisone, medrysone, 6 α -
30 methylprednisolone, mometasone, paramethasone, prednisolone, prednisone,

1 tetrahydrocortisol, triamcinolone, benoxinate, benzocaine, bupivacaine,
2 chlorprocaine, cocaine, dibucaine, dyclonine, etidocaine, lidocaine,
3 mepivacaine, pramoxine, prilocaine, procaine, proparacaine, tetracaine,
4 alfentanil, chloroform, clonidine, cyclopropane, desflurane, diethyl ether,
5 droperidol, enflurane, etomidate, fentanyl, halothane, isoflurane, ketamine
6 hydrochloride, meperidine, methohexital, methoxyflurane, morphine, propofol,
7 sevoflurane, sufentanil, thiamylal, thiopental, acetaminophen, allopurinol,
8 apazone, aspirin, auranofin, aurothioglucose, colchicine, diclofenac, diflunisal,
9 etodolac, fenoprofen, flurbiprofen, gold sodium thiomalate, ibuprofen,
10 indomethacin, ketoprofen, meclofenamate, mefenamic acid, meselamine, methyl
11 salicylate, nabumetone, naproxen, oxyphenbutazone, phenacetin,
12 phenylbutazone, piroxicam, salicylamide, salicylate, salicylic acid, salsalate,
13 sulfasalazine, sulindac, tolmetin, acetophenazine, chlorpromazine, fluphenazine,
14 mesoridazine, perphenazine, thioridazine, trifluorperazine, triflupromazine,
15 disopyramide, encainide, flecainide, indecainide, mexiletine, moricizine,
16 phenytoin, procainamide, propafenone, quinidine, tocainide, cisapride,
17 domperidone, dronabinol, haloperidol, metoclopramide, nabilone,
18 prochlorperazine, promethazine, thiethylperazine, trimethobenzamide,
19 buprenorphine, butorphanol, codeine, dezocine, diphenoxylate, drocode,
20 hydrocodone, hydromorphone, levallorphan, levorphanol, loperamide,
21 meptazinol, methadone, nalbuphine, nalmefene, nalorphine, naloxone,
22 naltrexone, oxybutynin, oxycodone, oxymorphone, pentazocine, propoxyphene,
23 isosorbide dinitrate, nitroglycerin, theophylline, phenylephrine, ephedrine,
24 pilocarpine, furosemide, tetracycline, chlorpheniramine, ketorolac, bromocriptine,
25 guanabenz, prazosin, doxazosin, and flufenamic acid.

26 Other representative drugs include benzodiazepines, such as alprazolam,
27 brotizolam, chlordiazepoxide, clobazam, clonazepam, clorazepate, demoxepam,
28 diazepam, flumazenil, flurazepam, halazepam, lorazepam, midazolam,
29 nitrazepam, nordazepam, oxazepam, prazepam, quazepam, temazepam,
30 triazolam, and the like; an antimuscarinic agent such as anisotropine, atropine,

1 clidinium, cyclopentolate, dicyclomine, flavoxate, glycopyrrolate, hexocyclium,
2 homatropine, ipratropium, isopropamide, mepenzolate, methantheline,
3 oxyphenyclimine, pirenzepine, propantheline, scopolamine, telenzepine,
4 tridihexethyl, tropicamide, and the like; an estrogen such as chlorotrianisene,
5 siethylstilbestrol, methyl estradiol, estrone, estrone sodium sulfate, estropipate,
6 mestranol, quinestrol, sodium equilin sulfate, 17 β -estradiol (or estradiol), semi-
7 synthetic estrogen derivatives such as the esters of natural estrogen, such as
8 estradiol-17 β -enanthate, estradiol-17 β -valerate, estradiol-3-benzoate, estradiol-
9 17 β -undecenoate, estradiol 16,17-hemisuccinate or estradiol-17 β -cypionate, and
10 the 17-alkylated estrogens, such as ethinyl estradiol, ethinyl estradiol-3-
11 isopropylsulphonate, and the like; an androgen such as danazol,
12 fluoxymesterone, methandrostenolone, methyltestosterone, nandrolone
13 decanoate, nandrolone phenpropionate, oxandrolone, oxymetholone, stanozolol,
14 testolactone, testosterone, testosterone cypionate, testosterone enanthate,
15 testosterone propionate, and the like; or a progestin such as ethynodiol
16 diacetate, gestodene, hydroxyprogesterone caproate, levonorgestrel,
17 medroxyprogesterone acetate, megestrol acetate, norethindrone, norethindrone
18 acetate, norethynodrel, norgestrel, progesterone, and the like.

19 Ethyl palmitate has been demonstrated herein as a suitable cosolvent for
20 GML. Ethyl palmitate may also be used as a cosolvent together with other
21 monoglycerides. Typically, monoglycerides have been available as a mixture of
22 monoglycerides of fatty acids with one monoglyceride being the principal
23 component, from which component the mixture derives its name. For example,
24 one commercial monoglyceride is Emerest 2421 glycerol monooleate (Emery
25 Division, Quantum Chemical Corp.), which is a mixture of glycerol oleates with a
26 glycerol monooleate content of 58% and a total monoesters content of 58%.

27 Other examples of commercial monoglycerides are Myverol 1899K
28 glycerol monooleate (Eastman Chemical Products) which has a glycerol
29 monooleate content of 61% and a total monoesters content of 93%, and Myverol
30 1892K glycerol monolinoleate which has a glycerol monolinoleate content of 68%

1 and a minimum total monoesters content of 90%. The monoesters are chosen
2 from those with from 10 to 20 carbon atoms. The fatty acids may be saturated or
3 unsaturated and include, for example, lauric acid, myristic acid, stearic acid, oleic
4 acid, linoleic acid and palmitic acid. Monoglyceride permeation enhancers
5 include glycerol monooleate, glycerol monolaurate and glycerol monolinoleate,
6 for example.

7 Transdermal drug delivery systems are typically maintained in contact with
8 the skin using an "in-line" contact adhesive, ie, a layer of adhesive positioned
9 between the drug reservoir of the delivery system and the skin. Glycerol
10 monooleate having a total monoesters content of less than about 65% interacts
11 adversely with known adhesive materials to such an extent that the adhesive
12 cannot function to maintain a delivery device on the skin. Therefore, when an in-
13 line adhesive is present as a part of the device of the invention so that a
14 permeation enhancer must pass through the adhesive, and when glycerol
15 monooleate is utilized as the second permeation enhancer, the glycerol
16 monooleate must have a total monoesters content of at least 65%.

17 Administration of the drug according to the invention comprises
18 administering the drug at a therapeutically effective rate to an area of a body
19 surface (eg, skin) or membrane and simultaneously administering the
20 monoglyceride and ethyl palmitate to the area of the body surface or membrane
21 at rates which are sufficient to substantially increase the permeability of the area
22 to the drug formulation.

23 According to the invention, the monoglyceride and ethyl palmitate
24 permeation enhancer and the drug to be delivered are placed in drug- and
25 permeation enhancer-transmitting relationship to the appropriate body surface,
26 preferably in a carrier therefor, and maintained in place for the desired period of
27 time. The drug and permeation enhancer mixture are typically dispersed within a
28 physiologically compatible matrix or carrier which may be applied directly to the
29 body surface or skin as an ointment, gel, cream, suppository or sublingual or
30 buccal tablet, for example, but are more preferably administered from a

1 transdermal therapeutic delivery device as more fully described below. When
2 used in the form of a liquid, ointment, cream, or gel applied directly to the skin, it
3 is preferable, although not required, to occlude the site of administration. Such
4 compositions can also contain other permeation enhancers, stabilizers, dyes,
5 diluents, pigments, vehicles, inert fillers, excipients, gelling agents,
6 vasoconstrictors, and other components of typical compositions as are known to
7 the art.

8 The monoglyceride / ethyl palmitate permeation enhancer of this invention
9 has a permeation-enhancing effect on the transport of drugs through body
10 surface tissues generally, in addition to the skin. However, because skin is one
11 of the most effective barriers to the permeation of drugs into the body, the effect
12 of a monoglyceride and ethyl palmitate on skin permeation makes it extremely
13 useful in transdermal delivery. The following description of embodiments of the
14 invention is therefore directed primarily to improving systemic delivery of these
15 drugs by permeation through the skin.

16 One embodiment of a transdermal delivery device of the present invention
17 is illustrated in FIG. 1. In FIG. 1, device 1 is comprised of a drug- and
18 permeation enhancer-containing reservoir ("drug reservoir") 2 which is preferably
19 in the form of a matrix containing the drug and the enhancer dispersed therein. A
20 backing layer 3 is provided adjacent one surface of drug reservoir 2. Adhesive
21 overlay 4 maintains the device 1 on the skin and may be fabricated together with,
22 or provided separately from, the remaining elements of the device. With certain
23 formulations, the adhesive overlay 4 may be preferable to an in-line contact
24 adhesive, such as adhesive layer 28 as shown in FIG. 3. Backing layer 3 may be
25 permeable or impermeable to the drug and is preferably slightly larger than drug
26 reservoir 2, and in this manner prevents the materials in drug reservoir 2 from
27 adversely interacting with the adhesive in overlay 4. A strippable or removable
28 liner 5 is also provided with device 1 and is removed just prior to application of
29 device 1 to the skin.

1 Figure 2 illustrates another embodiment of the invention, device 10, shown
2 in placement on the skin 17. In this embodiment, the transdermal drug delivery
3 device 10 comprises multi-laminate drug formulation / permeation enhancer
4 reservoir 11 having at least two zones 12 and 14. Zone 12 consists of a drug
5 reservoir substantially as described with respect to FIG. 1. Zone 14 comprises a
6 permeation enhancer reservoir which is preferably made from substantially the
7 same matrix as is used in zone 12. Zone 14 comprises monoglyceride and ethyl
8 palmitate dispersed throughout and is substantially free of any undissolved drug.
9 A rate-controlling membrane 13 for controlling the release rate of the
10 monoglyceride / ethyl palmitate permeation enhancer from zone 14 to zone 12 is
11 placed between the two zones. A rate-controlling membrane (not shown) for
12 controlling the release rate of the permeation enhancer from zone 12 to the skin
13 may also optionally be utilized and would be present between the skin 17 and
14 zone 12.

15 The rate-controlling membrane 13 may be fabricated from permeable,
16 semipermeable or microporous materials which are known in the art to control
17 the rate of agents into and out of delivery devices and having a permeability to
18 the permeation enhancer lower than the matrix material of zone 12. Suitable
19 materials include, but are not limited to, polyethylene, polyvinyl acetate and
20 ethylene vinyl acetate copolymers.

21 An advantage of the device described in FIG. 2 is that the drug-loaded
22 zone 12 is concentrated at the skin surface rather than throughout the entire
23 mass of a combined drug and enhancer reservoir such as reservoir 2 in FIG. 1.
24 This reduces the amount of drug in the device while maintaining an adequate
25 supply of permeation enhancer.

26 Superimposed over the drug formulation/enhancer reservoir 11/12 of
27 device 10 is an impermeable backing 15 and an adhesive overlay 16 as
28 described above with respect to FIG. 1. In addition, a removable liner (not
29 shown) would preferably be provided on the device prior to use as described with
30 respect to FIG. 1 and removed prior to application of the device 10 to the skin 17.

1 In the embodiments of FIGS. 1 and 2, the carrier or matrix material has
2 sufficient viscosity to maintain its shape without oozing or flowing. If, however,
3 the matrix or carrier is a low viscosity flowable material, the composition can be
4 fully enclosed in a permeable or microporous skin-contacting membrane, as
5 known to the art from U.S. Pat. No. 4,379,454 (noted above), for example.

6 An example of a presently preferred transdermal delivery device 20 is
7 illustrated in FIG. 3. Device 20 comprises a drug reservoir 22 containing both the
8 drug and the monoglyceride / ethyl palmitate permeation enhancer. Reservoir 22
9 is preferably in the form of a matrix containing the drug and the permeation
10 enhancer dispersed therein. Reservoir 22 is sandwiched between a backing
11 layer 24, which is preferably impermeable to both the drug and the permeation
12 enhancer mixture, and an in-line contact adhesive layer 28. In FIG. 3, the drug
13 reservoir 22 is formed of a material, such as a rubbery polymer, that is sufficiently
14 viscous to maintain its shape. The device 20 adheres to the surface of the skin
15 17 by means of the contact adhesive layer 28. The adhesive for layer 28 should
16 be chosen so that it is compatible and does not interact with any of the drug or, in
17 particular, the monoglyceride / ethyl palmitate permeation enhancer. The
18 adhesive layer 28 may optionally contain permeation enhancer and/or drug. A
19 removable liner (not shown) is normally provided along the exposed surface of
20 adhesive layer 28 and is removed prior to application of device 20 to the skin 17.
21 In an alternative embodiment, a rate-controlling membrane (not shown) is
22 present and the drug reservoir 22 is sandwiched between backing layer 24 and
23 the rate-controlling membrane, with adhesive layer 28 present on the skin-side of
24 the rate-controlling membrane.

25 Alternatively, reservoir 22 may be in the form of a matrix containing the
26 drug and permeation enhancer dispersed within a suitable adhesive, preferably a
27 pressure sensitive adhesive. Such pressure sensitive adhesives include, but are
28 not limited to, polysiloxanes, polyacrylates, polyurethanes, acrylic adhesives
29 including crosslinked or non-crosslinked acrylic copolymers, vinyl acetate
30 adhesives, ethylene vinylacetate copolymers, and natural or synthetic rubbers

1 including polybutadienes, polyisoprenes, and polyisobutylene adhesives, and
2 mixtures and graft copolymers thereof.

3 The matrix formulations according to this embodiment comprise the
4 adhesive containing drug and permeation enhancer laminated to a backing on
5 one surface and to a release liner on the other. In addition to the drug and
6 permeation enhancer, the matrix or carrier may also contain dyes, anti-irritants,
7 pigments, inert fillers, excipients and other conventional components of
8 pharmaceutical products or transdermal devices known to the art. For example,
9 the matrix may also be provided with hydrophilic water absorbing polymers
10 known in the art such as polyvinyl alcohol and polyvinyl pyrrolidone individually or
11 in combination and/or an anti-irritant, preferably a corticosteroid such as
12 hydrocortisone.

13 Various materials suited for the fabrication of the various layers of the
14 transdermal devices of FIGS. 1, 2 or 3 are known in the art or are disclosed in
15 the aforementioned transdermal device patents previously incorporated herein by
16 reference.

17 The matrix making up the drug/ permeation enhancer reservoir can be a
18 gel or a polymer. Suitable materials are compatible with the drug, GML or other
19 monoglyceride, ethyl palmitate, and any other components in the system.
20 Suitable matrix materials include, without limitation, natural and synthetic rubbers
21 or other polymeric material, thickened mineral oil, or petroleum jelly, for example.
22 The matrix is preferably polymeric and is more preferably an anhydrous polymer.
23 A preferred embodiment according to this invention is fabricated from an
24 ethylene vinyl acetate (EVA) copolymer, of the type described in U.S. Pat. No.
25 4,144,317, and is preferably selected from those EVAs having a vinyl acetate
26 (VA) content in the range of about 9 to 60%, preferably about 28 to 60% VA.
27 Particularly good results may be obtained using EVA of 40% vinyl acetate
28 content.

29 In addition to a drug and monoglyceride / ethyl palmitate, which are
30 essential to the invention, the matrix may also contain stabilizers, dyes,

1 permeation enhancers, pigments, inert fillers, anti-irritants, tackifiers, excipients
2 and other conventional components of transdermal delivery devices as are
3 known in the art. For example, the matrix may also be provided with hydrophilic
4 water absorbing polymers known in the art such as polyvinyl alcohol and
5 polyvinyl pyrrolidone individually or in combination.

6 The amounts of the drug that are present in the therapeutic device, and
7 that are required to achieve a therapeutic effect, depend on many factors, such
8 as the minimum necessary dosage of the particular drug; the permeability of the
9 matrix, of the adhesive layer and of the rate-controlling membrane, if present;
10 and the period of time for which the device will be fixed to the skin. There is, in
11 fact, no upper limit to the maximum amounts of drug present in the device. The
12 minimum amount of each drug is determined by the requirement that sufficient
13 quantities of drug must be present in the device to maintain the desired rate of
14 release over the given period of application.

15 The drug is generally dispersed through the matrix at a concentration in
16 excess of saturation, i.e. at unit activity. The amount of excess is determined by
17 the intended useful life of the system. However, the drug may be present at
18 initial levels below saturation without departing from this invention. Generally, the
19 drug may be present at initially subsaturated levels when: 1) the skin flux of the
20 drug is sufficiently low such that the reservoir drug depletion is slow and small; 2)
21 non-constant delivery of the drug is desired or acceptable; and/or 3) saturation of
22 the reservoir is achieved in use due to migration of water into the reservoir from
23 the skin, where water is abundantly available.

24 The monoglyceride and ethyl palmitate permeation enhancer is dispersed
25 throughout the matrix, preferably at a concentration sufficient to provide
26 permeation-enhancing concentrations of permeation enhancer in the reservoir
27 throughout the anticipated administration period.

28 In the present invention, the drug is delivered through the skin or other
29 body surface at a therapeutically effective rate (that is, a rate that provides an
30 effective therapeutic result) and the monoglyceride / ethyl palmitate permeation

1 enhancer is delivered at a permeation-enhancing rate (that is, a rate that
2 provides increased permeability of the application site to the drug) for a
3 predetermined time period.

4 A preferred embodiment of the present invention is a multilaminate, such
5 as that illustrated in FIG. 3 (either with or without a rate-controlling membrane)
6 wherein reservoir 22 comprises, by weight, 30- 90% polymer (preferably EVA
7 having a vinyl acetate content of 40%), 1 - 40% drug, 1-50%, more preferably 1-
8 25%, and most preferably 4-15% GML, and 1-40%, more preferably 1-20%, and
9 most preferably 4-12% ethyl palmitate. The in-line adhesive layer 28 comprises
10 an adhesive which is compatible with the permeation enhancer.

11 Another preferred embodiment of the present invention is a monolith, (not
12 depicted) wherein the drug reservoir comprises, by weight, 30-90%, more
13 preferably, 30- 70% of a pressure sensitive adhesive, 1-40% drug, 1-40%, more
14 preferably 1-25%, and most preferably 4-15% GML, and 1-40%, more preferably
15 1-20%, and most preferably 4-12% ethyl palmitate, and optionally 1-15 wt% of a
16 water absorbing polymer such as polyvinyl pyrrolidone.

17 The devices of this invention can be designed to effectively deliver a drug
18 for an extended time period of up to 7 days or longer. Seven days is generally
19 the maximum time limit for application of a single device because the skin site is
20 adversely affected by a period of occlusion greater than 7 days. Where it is
21 desired to have drug delivery for greater than 7 days (such as, for example, when
22 a hormone is being applied for a contraceptive effect), when one device has
23 been in place on the skin for its effective time period, it is replaced with a fresh
24 device, preferably on a different skin site.

25 The transdermal therapeutic devices of the present invention are prepared
26 in a manner known in the art, such as by those procedures, for example,
27 described in the transdermal device patents listed previously herein. The
28 following examples are offered to illustrate the practice of the present invention
29 and are not intended to limit the invention in any manner.

30

1 EXAMPLE 1

2

3 The effect of various permeation enhancers on the transdermal flux of
 4 progesterone was studied. The drug/permeation enhancer reservoirs were
 5 prepared by mixing ethylene vinyl acetate having a vinyl acetate content of 40
 6 percent ("EVA 40", USI Chemicals, Illinois) in an internal mixer (Brabender type)
 7 until the EVA 40 pellets fused. Progesterone, GML (Danisco Ingredients) and
 8 ethyl palmitate (EP) (CTC Organics, Atlanta, GA), were then added as shown in
 9 Table 1A. The mixture was blended, cooled, and calendered to a 5 mil thick film.

10 The film was then laminated to a Cotran® (3M, St. Paul, MN) backing on
 11 one side and an acrylate contact adhesive (3M, St. Paul, MN) on the opposite
 12 side. The laminate was then cut into 2.54 cm² circles using a steel punch.

13 Drug in adhesive systems were prepared by adding GML, PVP (XL-10,
 14 K29-32 ISP Technologies, Inc, Calvert City, KY), and EP to polysiloxane
 15 adhesive (Dow Corning, Midland, MI) in THF/ethyl acetate solvent at a solvent
 16 ratio of approximately 50/50. The solution was mixed for approximately 1 hour at
 17 which time the drug (progesterone) is added with additional mixing for
 18 approximately 1 hour. The compositions of these systems are also shown in
 19 Table 1A. The solution was then cast to 12 mil thickness on a release liner film
 20 (3M fluorocoated 1022) and placed in an oven at about 70° C for approximately
 21 45 minutes, then laminated to a polyethylene backing (Cotran 9220, 3M). The
 22 laminate was then cut into 2.54 cm² circles using a steel punch.

23

TABLE 1A

24 Drug/Permeation Enhancer Reservoir Composition (weight percent)

FORMULATION	WEIGHT PERCENT
A. progesterone /EVA 40	5/95
B. progesterone /GML/EP/EVA 40	5/20/12/63
C. progesterone /polysiloxane	5/95
D. progesterone /GML/EP/PVP/polysiloxane	5/3/7/2.5/82.5

25

1 Circular pieces of human epidermis were mounted on the receptor
 2 compartment of horizontal permeation cells with the stratum corneum facing the
 3 donor compartment of the cell. The release liner of the laminate was removed
 4 and the systems were centered over the stratum corneum side of the epidermis.
 5 The donor compartment was then clamped with the receptor compartment. A
 6 known volume of receptor solution (1% Tween 20 in water) was equilibrated at
 7 35 °C and placed in the receptor compartment. Air bubbles were removed from
 8 the receptor compartment, the cell was capped and placed in a water bath
 9 shaker at 35 °C.

10 At given time intervals, the entire receptor solution was removed from the
 11 cells and replaced with an equal volume of fresh receptor solutions previously
 12 equilibrated at 35 °C. The receptor solutions are stored in capped vials at 4 °C
 13 until assayed for progesterone content by high performance liquid
 14 chromatography (HPLC). The tests were run in triplicate on 2 skin donors.

15 From the drug concentration and the volume of the receptor solutions, the
 16 area of permeation and the time interval, the flux of the drug through the
 17 epidermis was calculated as follows: (drug concentration x volume of receptor)/(
 18 area x time) = flux ($\mu\text{g}/\text{cm}^2 \cdot \text{hr}$). The average flux ratios of each formulation
 19 comprising the permeation enhancer compared to the formulation without
 20 permeation enhancers for each of the skins tested is depicted in
 21 Table 1B.

22

23

TABLE 1B

24

Average Flux Ratios

FORMULATION	FLUX RATIO SKIN I (FORM. X/CONTROL)	FLUX RATIO SKIN II (FORM. X/CONTROL)
A.	1.00	1.00
B.	5.67	6.13
C.	1.00	1.00
D.	1.70	2.09

25

26

EXAMPLE 2

1

2

3 The effect of various permeation enhancer mixtures on the transdermal
4 flux of buspirone was studied. The drug/permeation enhancer reservoirs were
5 prepared according to the procedure set forth in Example 1. Buspirone, GML,
6 and ethyl palmitate, were added as shown in Table 2A.

7

8

TABLE 2A

9

Drug/Permeation Enhancer Reservoir Composition (weight percent)

FORMULATION	WEIGHT PERCENT
E. buspirone /EVA 40	20/80
F. buspirone /GML/EVA 40	20/20/60
G. buspirone /GML/EP/EVA 40	20/20/12/48
H. buspirone /EP/EVA 40	20/12/68

10

11 The skin flux experiments according to Example 1 were conducted using
12 0.05 M KH_2PO_4 / K_2HPO_4 , pH 6.5, as the receptor solution. The average flux
13 ratios of each formulation comprising the permeation enhancer mixture
14 compared to the formulation without permeation enhancers for each of the skins
15 tested is depicted in Table 2B.

16

17

18

19

20

TABLE 2B

21

Average Flux Ratios

FORMULATION	FLUX RATIO SKIN I (FORM. X/CONTROL)	FLUX RATIO SKIN II (FORM. X/CONTROL)
E.	1.00	1.00
F.	9.19	8.16
G.	10.03	8.15
H.	1.28	1.19

22

1

EXAMPLE 3

2

3 The effect of various permeation enhancer mixtures on the transdermal
4 flux of estradiol was studied. The drug/permeation enhancer reservoirs were
5 prepared according to the procedures set forth in Example 1. Estradiol, GML,
6 PVP, and ethyl palmitate, were added as shown in Table 3A.

7

TABLE 3A

8

Drug/Permeation Enhancer Reservoir Composition (weight percent)

FORMULATION	WEIGHT PERCENT
I. estradiol /EVA 40	5/95
J. estradiol /GML/EP/EVA 40	5/20/12/63
K. estradiol /polysiloxane	2/98
L. estradiol /GML/EP/PVP/poisyloxane	2/3/7/2.5/85.5

9

The skin flux experiments according to Example 1 were conducted using
10 1% Tween 20 in water as the receptor solution. The average flux ratios of each
11 formulation comprising the permeation enhancer mixture compared to the
12 formulation without permeation enhancers for each of the skins tested is depicted
13 in Table 3B.

14

TABLE 3B

15

Average Flux Ratios

FORMULATION	FLUX RATIO SKIN I (FORM. X/CONTROL)	FLUX RATIO SKIN II (FORM. X/CONTROL)
I.	1.00	1.00
J.	2.05	2.11
K.	1.00	1.00
L.	1.31	1.38

16

17

18

EXAMPLE 4

19

20 The effect of GML and ethyl palmitate on the transdermal flux of
21 oxybutynin from drug in adhesive matrix formulations was determined. The

1 systems having the compositions shown in Table 4A, were prepared by the
2 procedure set forth in Example 1.

3

4

TABLE 4A

5

Drug/Permeation Enhancer Reservoir Composition (weight percent)

DRUG RESERVOIR	WEIGHT PERCENT
M. oxybutynin base/polysiloxane	20/80
N. oxybutynin base/GML/EP/PVP/polysiloxane	20/3/7/2.5/67.5

6

7 The skin flux experiments according to Example 1 were conducted using
8 0.05 M KH₂PO₄ / K₂HPO₄, pH 6, as the receptor solution. The average flux ratios
9 of each formulation comprising the permeation enhancer mixture compared to
10 the formulation without permeation enhancers for each of the skins tested is
11 depicted in Table 4B.

12

TABLE 4B

13

Average Flux Ratios

FORMULATION	FLUX RATIO SKIN I (FORM. X/CONTROL)	FLUX RATIO SKIN II (FORM. X/CONTROL)
M.	1.00	1.00
N.	1.86	1.46

14

15

EXAMPLE 5

16

17 The effect of GML and ethyl palmitate on the transdermal flux of buspirone
18 from drug in adhesive matrix formulations was determined. The drug/permeation
19 enhancer reservoirs, having the compositions shown in Table 5A, were prepared
20 by the procedure described in Example 1.

1

2

TABLE 5A

3

Drug/Permeation Enhancer Reservoir Composition (weight percent)

DRUG RESERVOIR	WEIGHT PERCENT
O. buspirone/polysiloxane	5/95
P. buspirone/GML/EP/PVP/polysiloxane	5/3/7/2.5/82.5

4

5

6

7

8

9

The skin flux experiments according to Example 1 were conducted using 0.05 M KH_2PO_4 / K_2HPO_4 , pH 6.5, as the receptor solution. The average flux ratios of each formulation comprising the permeation enhancer mixture compared to the formulation without permeation enhancers for each of the skins tested is depicted in Table 5B.

10

TABLE 5B

11

Average Flux Ratios

FORMULATION	FLUX RATIO SKIN I (FORM. X/CONTROL)	FLUX RATIO SKIN II (FORM. X/CONTROL)
O.	1.00	1.00
P.	3.53	3.77

12

13

EXAMPLE 6

14

15

16

17

18

19

The transdermal flux of testosterone from drug in adhesive matrix formulations comprising GML and either dodecyl acetate (Inoue Perfumery Mfg. Co. LTD, Tokyo, Japan) or ethyl palmitate was determined. The drug/permeation enhancer reservoirs, having the compositions shown in Table 2, were prepared by the procedure described in Example 1.

1 TABLE 6
2 Drug/Permeation Enhancer Reservoir Composition (weight percent)

DRUG RESERVOIR	WEIGHT PERCENT
testosterone/EVA 40	2/98
testosterone/GML/DA/PVP/polysiloxane	5/4/7/10/74
testosterone/GML/DA/PVP/polysiloxane	5/8/7/5/75
testosterone/GML/DA/PVP/polysiloxane	5/12/7/5/71
testosterone /GML/EP/PVP/polysiloxane	5/4/7/10/74
testosterone /GML/EP/PVP/polysiloxane	5/8/7/5/75

3
4 The skin flux experiments according to Example 1 were conducted using
5 0.10% phenol/water as the receptor solution. Figure 4 depicts the results.
6 The invention has been described in detail with particular reference to
7 certain preferred embodiments thereof, but it will be understood that variations
8 and modifications can be affected within the scope and spirit of the invention.

1 What is claimed is:

2

3 1. A composition of matter for transdermally delivering at least one
4 drug at a therapeutically effective rate by permeation through a body surface or
5 membrane comprising, in combination:

6 (a) at least one drug; and

7 (b) a permeation-enhancing amount of a permeation enhancer comprising
8 a monoglyceride and ethyl palmitate, wherein the drug and permeation enhancer
9 are dispersed within a carrier.

10 2. A composition according to claim 1 wherein the monoglyceride is
11 selected from glycerol monooleate, glycerol monolinoleate, and glycerol
12 monolaurate.

13 3. A composition according to claim 1 wherein the drug is present in
14 an amount in excess of its saturation in the carrier.

15 4. A composition according to claim 1 comprising 1-40% by weight of
16 at least one drug, 1-50% by weight of a monoglyceride, 1-50% by weight ethyl
17 palmitate, and 30-90% by weight of a polymeric carrier.

18 5. A composition according to claim 4 comprising 1-25% by weight
19 glycerol monolaurate and 1-20% by weight ethyl palmitate.

20 6. A composition according to claim 5 comprising 4-15% by weight
21 glycerol monolaurate and 4-12% by weight ethyl palmitate

22 7. A composition according to claim 4 wherein the drug is selected
23 from the group consisting of testosterone, estradiol, progesterone, fentanyl,
24 oxybutynin, and buspirone.

25 8. A device for the transdermal administration of at least one drug at a
26 therapeutically effective rate by permeation through a body surface or
27 membrane, comprising:

28 a) a drug reservoir comprising at least one drug and a permeation-
29 enhancing amount of a permeation enhancer comprising a monoglyceride and
30 ethyl palmitate;

- 1 b) a backing on or adjacent the skin distal surface of the drug reservoir;
2 c) means for maintaining the reservoir in drug- and permeation enhancer -
3 transmitting relation with the body surface or membrane.

4 9. A device according to claim 8 wherein the monoglyceride is
5 selected from the group consisting of glycerol monooleate, glycerol
6 monolinoleate, and glycerol monolaurate.

7 10. A device according to claim 8 wherein the drug is selected from the
8 group consisting of anxiolytics, anticholinergics, analgesics, and anti-
9 spasmodics.

10 11. A device according to claim 8 wherein the drug is a steroid.

11 12. A device according to claim 8 wherein the drug is selected from the
12 group consisting of testosterone, estradiol, progesterone, fentanyl, oxybutynin,
13 and buspirone.

14 13. A device according to claim 8 wherein the means for maintaining
15 the reservoir in drug- and permeation enhancer -transmitting relation with the
16 body surface or membrane is an in-line adhesive.

17 14. A device according to claim 8 wherein the drug reservoir comprises
18 a pressure sensitive adhesive which also provides said means for maintaining
19 the reservoir in drug- and permeation enhancer -transmitting relation with the
20 body surface or membrane.

21 15. A device according to claim 14 wherein the pressure sensitive
22 adhesive is selected from the group consisting of polysiloxanes, polyacrylates,
23 polyurethanes, crosslinked or non-crosslinked acrylic copolymers, vinyl acetate
24 adhesives, ethylene vinylacetate copolymers, and natural or synthetic rubbers
25 including polybutadienes, polyisoprenes, and polyisobutylene adhesives, and
26 mixtures and graft copolymers thereof.

27 16. A device according to claim 8 wherein the drug reservoir
28 comprises:

- 29 i) 1-40% by weight of at least one drug,
30 ii) 1-40% by weight ethyl palmitate,

- 1 iii) 1-50% by weight glycerol monolaurate, and
2 iv) 30-90% by weight polymeric carrier.

3 17. A device according to claim 16 comprising 1-25% by weight
4 glycerol monolaurate and 1-20% by weight ethyl palmitate.

5 18. A device according to claim 17 comprising 4-15% by weight
6 glycerol monolaurate and 4-12% by weight ethyl palmitate.

7 19. A device according to claim 16 wherein said polymeric carrier
8 comprises ethylene vinyl acetate.

9 20. A device according to claim 8 wherein the drug reservoir
10 comprises:

- 11 I) 1-40% by weight of a drug,
12 ii) 1-40% by weight ethyl palmitate,
13 iii) 1-40% by weight glycerol monolaurate, and
14 iv) 30-90% by weight pressure sensitive adhesive.

15 21. A device according to claim 20 comprising 1-25% by weight
16 glycerol monolaurate and 1-20% by weight ethyl palmitate.

17 22. A device according to claim 21 comprising 4-15% by weight
18 glycerol monolaurate and 4-12% by weight ethyl palmitate.

19 23. A device according to claim 20 further comprising 1-15% by weight
20 of a water absorbing polymer selected from the group consisting of polyvinyl
21 pyrrolidone and polyvinyl alcohol.

22 24. A device for the transdermal administration of at least one drug at a
23 therapeutically effective rate by permeation through a body surface or
24 membrane, comprising:

- 25 a) a first reservoir comprising at least one drug and a permeation-
26 enhancing amount of a permeation enhancer comprising a monoglyceride and
27 ethyl palmitate;
28 b) a second reservoir comprising an additional amount of the permeation
29 enhancer;
30 c) a rate controlling membrane between the first and second reservoirs;

1 d) a backing on or adjacent the skin distal surface of the first reservoir;
2 and

3 e) means for maintaining the reservoir in drug- and permeation enhancer -
4 transmitting relation with the body surface or membrane.

5 25. A device according to claim 24 wherein the monoglyceride is
6 selected from glycerol monooleate, glycerol monolinoleate, and glycerol
7 monolaurate.

8 26. A device according to claim 24 wherein the drug is selected from
9 the group consisting of anxiolytics, anticholinergics, analgesics, and anti-
10 spasmodics.

11 27. A device according to claim 24 wherein the drug is a steroid.

12 28. A device according to claim 24 wherein the drug is selected from
13 the group consisting of testosterone, estradiol, progesterone, fentanyl,
14 oxybutynin, and buspirone.

15 29. A method for the transdermal administration of at least one drug at
16 a therapeutically effective rate comprising simultaneously coadministering to a
17 body surface or membrane a drug and a permeation enhancing amount of a
18 permeation enhancer comprising a monoglyceride and ethyl palmitate.

19 30. A method according to claim 29 further comprising maintaining said
20 coadministration of drug and permeation enhancer for a period of time sufficient
21 to produce a beneficial effect.

22 31. A method according to claim 29 wherein the monoglyceride is
23 selected from glycerol monooleate, glycerol monolinoleate, and glycerol
24 monolaurate.

25 32. A method according to claim 29 wherein the drug is selected from
26 the group consisting of anxiolytics, anticholinergics, analgesics, and anti-
27 spasmodics.

28 33. A method according to claim 29 wherein the drug is a steroid.

- 1 34. A method according to claim 29 wherein the drug is selected from
- 2 the group consisting of testosterone, estradiol, progesterone, fentanyl,
- 3 oxybutynin, and buspirone.



FIG. 1




FIG. 2





FIG. 3



●	testosterone/EVA 40	2/98
■	testosterone/GML/DA/PVP/polysiloxane	5/4/7/10/74
▲	testosterone/GML/DA/PVP/polysiloxane	5/8/7/75
▼	testosterone/GML/DA/PVP/polysiloxane	5/12/7/5/71
◆	testosterone/GML/EP/PVP/polysiloxane	5/4/7/10/74
⊙	testosterone/GML/EP/PVP/polysiloxane	5/8/7/5/75

FIG. 4

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/27052

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 A61K47/14 //(A61K47/14,47:14)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 4 751 087 A (WICK STEVEN M) 14 June 1988 see column 2, line 1-67 see column 5, line 10-50 ---	1-34
Y	WO 96 40259 A (ALZA CORP ;BURKOTH TERRY L (US); TASKOVICH LINA T (US); CRISOLOGO) 19 December 1996 cited in the application see page 5, line 25 - page 28, line 10 ---	1-34
Y	US 5 026 556 A (DRUST EUGENE G ET AL) 25 June 1991 cited in the application see column 5, line 40-60 ---	1-34
Y	WO 96 37231 A (ALZA CORP) 28 November 1996 see page 11, line 11-22 ---	1-34
-/--		

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

3 March 1999

Date of mailing of the international search report

11/03/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Engl, B

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/27052

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 4 820 720 A (SANDERS HAROLD F ET AL) 11 April 1989 cited in the application see column 2, line 34-38 ---	1-34
Y	WO 92 07589 A (ALZA CORP) 14 May 1992 see page 12, line 6-18 ---	1-34
Y	WO 93 23025 A (ALZA CORP) 25 November 1993 see page 5, column 18-31 ---	7,12,28, 34
Y	EP 0 573 133 A (SCHERING AG) 8 December 1993 see page 2, line 53 - page 3, line 18 -----	1-34

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/27052

Patent document cited in search report	A	Publication date	Patent family member(s)	Publication date
US 4751087	A	14-06-1988	AU 593810	B 22-02-1990
			AU 5772586	A 18-11-1986
			CA 1273871	A 11-09-1990
			DE 3685545	A 09-07-1992
			EP 0219539	A 29-04-1987
			IE 59725	B 23-03-1994
			JP 2588180	B 05-03-1997
			JP 62502965	T 26-11-1987
			WO 8606281	A 06-11-1986
WO 9640259	A	19-12-1996	US 5785991	A 28-07-1998
			AU 5957296	A 30-12-1996
			CA 2221096	A 19-12-1996
			DE 19622902	A 12-12-1996
			EP 0835136	A 15-04-1998
			FR 2735027	A 13-12-1996
			GB 2305122	A 02-04-1997
			US 5843468	A 01-12-1998
US 5026556	A	25-06-1991	CA 2002300	A,C 10-05-1990
			DE 68907858	T 18-11-1993
			EP 0368406	A 16-05-1990
			JP 2191214	A 27-07-1990
WO 9637231	A	28-11-1996	AU 697200	B 01-10-1998
			AU 5792896	A 11-12-1996
			CA 2217029	A 28-11-1996
			CN 1185741	A 24-06-1998
			EP 0828516	A 18-03-1998
US 4820720	A	11-04-1989	US 4764379	A 16-08-1988
			AU 1379988	A 02-03-1989
			CA 1313352	A 02-02-1993
			DE 3872109	A 23-07-1992
			EP 0305026	A 01-03-1989
			GR 3004941	T 28-04-1993
			JP 1068314	A 14-03-1989
			JP 2650713	B 03-09-1997
			KR 9614996	B 23-10-1996
WO 9207589	A	14-05-1992	US 5122382	A 16-06-1992
			AT 171069	T 15-10-1998
			AU 9041991	A 26-05-1992
			CA 2088778	A 30-04-1992
			DE 69130232	D 22-10-1998
			EP 0577602	A 12-01-1994
			ES 2123547	T 16-01-1999
			JP 6502429	T 17-03-1994
			NO 303527	B 27-07-1998
			NZ 240361	A 26-07-1995
			PT 99340	A 30-09-1992
			US 5320850	A 14-06-1994
			US 5314694	A 24-05-1994
			US 5198223	A 30-03-1993
WO 9323025	A	25-11-1993	AU 666735	B 22-02-1996
			AU 4247393	A 13-12-1993
			CA 2132865	A 25-11-1993

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/27052

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9323025 A		EP 0767659 A	16-04-1997
		FI 945311 A	11-11-1994
		JP 8502952 T	02-04-1996
		MX 9302812 A	01-11-1993
		NO 944249 A	14-11-1994
		NZ 252598 A	29-01-1997
		US 5411740 A	02-05-1995
		US 5500222 A	19-03-1996
		ZA 9303349 A	15-06-1994

EP 0573133 A	08-12-1993	DE 3836862 A	03-05-1990
		DE 3910578 A	04-10-1990
		AT 132751 T	15-01-1996
		AU 2059695 A	31-08-1995
		AU 3001192 A	11-02-1993
		AU 4374789 A	03-05-1990
		AU 7741698 A	01-10-1998
		CA 2001618 A	27-04-1990
		CN 1042075 A, B	16-05-1990
		CN 1157719 A	27-08-1997
		DD 286293 A	24-01-1991
		DE 58909570 D	22-02-1996
		DK 138590 A	06-06-1990
		WO 9004397 A	03-05-1990
		EP 0370220 A	30-05-1990
		EP 0394429 A	31-10-1990
		ES 2081823 T	16-03-1996
		FI 100456 B	15-12-1997
		GR 3019079 T	31-05-1996
		IL 92007 A	08-12-1995
		JP 3502700 T	20-06-1991
		KR 137463 B	01-06-1998
		MX 173621 B	18-03-1994
		NO 180567 B	03-02-1997
		NO 951592 A	26-06-1990
		PT 92131 A, B	30-04-1990
		US 5788984 A	04-08-1998
		HU 210549 B	29-05-1995
		PL 162400 B	30-11-1993
		PL 162410 B	30-11-1993
SK 608989 A	07-05-1997		
RU 2044541 C	27-09-1995		
